Author:
O’Shea Rosie,Crook Ashley,Jacobs Chris,Kentwell Maira,Gleeson Margaret,Tucker Katherine M.,Hampel Heather,Rahm Alanna Kulchak,Taylor Natalie,Lewis Sarah,Rankin Nicole M.
Abstract
Introduction“Mainstreaming” is a proposed strategy to integrate genomic testing into oncology. The aim of this paper is to develop a mainstreaming oncogenomics model by identifying health system interventions and implementation strategies for mainstreaming Lynch syndrome genomic testing.MethodsA rigorous theoretical approach inclusive of conducting a systematic review and qualitative and quantitative studies was undertaken using the Consolidated Framework for Implementation Research. Theory-informed implementation data were mapped to the Genomic Medicine Integrative Research framework to generate potential strategies.ResultsThe systematic review identified a lack of theory-guided health system interventions and evaluation for Lynch syndrome and other mainstreaming programs. The qualitative study phase included 22 participants from 12 health organizations. The quantitative Lynch syndrome survey included 198 responses: 26% and 66% from genetic and oncology health professionals, respectively. Studies identified the relative advantage and clinical utility of mainstreaming to improve genetic test access and to streamline care, and adaptation of current processes was recognized for results delivery and follow-up. Barriers identified included funding, infrastructure and resources, and the need for process and role delineation. The interventions to overcome barriers were as follows: embedded mainstream genetic counselors, electronic medical record genetic test ordering, results tracking, and mainstreaming education resources. Implementation evidence was connected through the Genomic Medicine Integrative Research framework resulting in a mainstreaming oncogenomics model.DiscussionThe proposed mainstreaming oncogenomics model acts as a complex intervention. It features an adaptable suite of implementation strategies to inform Lynch syndrome and other hereditary cancer service delivery. Implementation and evaluation of the model are required in future research.
Reference53 articles.
1. eviQ 2020 version 9 BRCA 1 and 2 genetic testing
2. Clinical practice guidelines in oncology. Genetic/Familial high risk assessment: breast, ovarian and pancreatic cancer. version 1.2020
3. Familial breast cancer clinical guideline2019
4. Adherence patterns to national comprehensive cancer network (NCCN) guidelines for referral to cancer genetic professionals;Febbraro;Gyn Onc,2015
5. Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling;Powell;Int J Gynecol Cancer,2013